Breaking News Instant updates and real-time market news.

VRNA

Verona Pharma

$12.53

-0.17 (-1.34%)

, TBPH

Theravance Biopharma

$27.02

0.08 (0.30%)

04:55
09/19/18
09/19
04:55
09/19/18
04:55

European Respiratory Society to hold a conference

ERS International Congress 2018 will be held in Paris, France on September 15-19.

VRNA

Verona Pharma

$12.53

-0.17 (-1.34%)

TBPH

Theravance Biopharma

$27.02

0.08 (0.30%)

MYL

Mylan

$37.80

0.59 (1.59%)

AZN

AstraZeneca

$37.49

-0.06 (-0.16%)

BDX

Becton Dickinson

$259.79

2.54 (0.99%)

BIIB

Biogen

$337.01

2.65 (0.79%)

BSX

Boston Scientific

$37.63

0.36 (0.97%)

GLPG

Galapagos NV

$116.56

0.81 (0.70%)

GSK

GlaxoSmithKline

$39.62

0.415 (1.06%)

MMM

3M

$211.54

1.99 (0.95%)

MDT

Medtronic

$96.91

0.91 (0.95%)

NVS

Novartis

$85.03

-0.1 (-0.12%)

ORN

Orion Group

$8.10

0.28 (3.58%)

PHG

Philips

$45.49

0.11 (0.24%)

PKI

PerkinElmer

$94.89

0.305 (0.32%)

REGN

Regeneron

$388.02

1.5 (0.39%)

RMD

ResMed

$113.48

0.71 (0.63%)

SNY

Sanofi

$43.96

0.17 (0.39%)

TEVA

Teva

$24.50

1.06 (4.52%)

  • 20

    Sep

  • 27

    Sep

  • 01

    Oct

  • 09

    Oct

  • 20

    Oct

  • 22

    Oct

  • 28

    Oct

  • 29

    Oct

  • 06

    Nov

  • 13

    Nov

  • 27

    Nov

  • 28

    Jan

  • 22

    Mar

  • 28

    Apr

  • 13

    May

VRNA Verona Pharma
$12.53

-0.17 (-1.34%)

02/20/18
BREN
02/20/18
INITIATION
Target $30
BREN
Buy
Verona Pharma initiated with a Buy at Berenberg
Berenberg analyst Patrick Trucchio initiated Verona Pharma with a Buy and $30 price target.
03/27/18
WEDB
03/27/18
NO CHANGE
Target $55
WEDB
Outperform
Verona Pharma price target raised to $55 from $48 at Wedbush
Wedbush analyst Liana Moussatos raised her price target for Verona Pharma to $55 from $48 as statistically significant, clinically meaningful Phase 2b results for nebulized RPL554 maintenance therapy of COPD reinforce the clinical benefits of dual PDE3/PDE4 inhibition in respiratory diseases. The analyst reiterates an Outperform rating on the shares.
03/27/18
RHCO
03/27/18
NO CHANGE
Target $37
RHCO
Buy
Verona Pharma price target raised to $37 from $26 at SunTrust
SunTrust analyst Yatin Suneja raised his price target on Verona Pharma to $37 after the company's "highly favorable" phase 2b results for RPL 554 in COPD maintenance. The analyst raises his probability of success on the treatment to 40% from 33% and adjusts his model based on the data while also keeping his Buy rating on Verona Pharma.
TBPH Theravance Biopharma
$27.02

0.08 (0.30%)

03/29/18
PIPR
03/29/18
INITIATION
Target $45
PIPR
Overweight
Theravance Biopharma assumed with an Overweight at Piper Jaffray
Piper Jaffray analyst Tyler Van Buren assumed coverage of Theravance Biopharma with an Overweight rating and $45 price target. The company's respiratory products Trelegy and revefenacin "provide solid valuation support with the potential for significant upside" from its proprietary 1473/JAK and 9855/nOH development candidate, the analyst contends. He has confidence in the Trelegy launch and revefenacin approval and recommends investors buy the shares.
05/09/18
LEER
05/09/18
NO CHANGE
Target $31
LEER
Outperform
Theravance Biopharma price target lowered to $31 from $41 at Leerink
Leerink analyst Geoffrey Porges lowered his price target for Theravance Biopharma to $31 from $41 after the company reported Q1 operational results and announced the discontinuation of its independent development of velusetrag in gastroparesis based on feedback from the FDA about the requirement for large phase III safety and efficacy study as a requirement for approval. The analyst reiterates an Outperform rating on the shares.
08/01/18
PIPR
08/01/18
NO CHANGE
Target $55
PIPR
Overweight
Theravance Biopharma price target raised to $55 from $45 at Piper Jaffray
Piper Jaffray analyst Tyler Van Buren raised his price target for Theravance Biopharma (TBPH) to $55 saying the proof of concept demonstrated for TD-9855 in neurogenic orthostatic hypotension compare favorably to Lundbeck's Northera. Considering Northera is run-rating at $250M-$300M about four years post launch with minimal patient penetration of the target population, a differentiated TD-9855 could ultimately achieve $500M-plus in peak sales, Van Buren tells investors in a research note. Further, the analyst believes an accelerated approval could be possible. He reiterates an Overweight rating on Theravance Biopharma.
MYL Mylan
$37.80

0.59 (1.59%)

08/24/18
08/24/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Netflix (NFLX) upgraded to Buy from Hold at SunTrust with analyst Matthew Thornton saying the pullback after the Q2 subscriber miss was driven in part by the interest in World Cup viewing. 2. Sanderson Farms (SAFM) upgraded to Overweight from Equal Weight at Stephens with analyst Farha Aslam citing the company's Q3 results and saying she believes weak chicken fundamentals are now priced into the shares. 3. Children's Place (PLCE) upgraded to Buy from Neutral at Monness Crespi analyst Jim Chartier saying the modest sell-off in shares following strong Q2 results provides a buying opportunity. 4. Mylan (MYL) upgraded to Outperform from In Line at Evercore ISI. 5. Embraer (ERJ) upgraded to Hold from Underperform at Santander. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/06/18
WELS
09/06/18
NO CHANGE
WELS
Teva, Mylan weakness related to low multiple in Sandoz sale, says Wells Fargo
Wells Fargo analyst David Maris attributes today's weakness in shares of generic drugmakers Teva (TEVA) and Mylan (MYL) to the low sales multiple at which Novartis' (NVS) Sandoz unit is selling a portfolio of generic and branded products to Aurobindo. While Teva and Mylan clearly have very different businesses than the largely commodity and dermatology portfolio Sandoz is selling for $900M, Maris believes some investors are looking at the deal as a proxy for what the commodity portions of their U.S. businesses might be worth, he tells investors. Maris, who has previously voiced caution about generics and generic drug pricing, sees Novartis' deal as another indication that the environment remains challenging.
08/30/18
GDHS
08/30/18
NO CHANGE
GDHS
Gordon Haskett questions Perrigo tie-up potential following call postponement
In a report published on August 20, Gordon Haskett analyst Don Bilson noted that Mylan (MYL) once claimed that it could generate $800M of synergies from a deal with Perrigo (PRGO) and while that dollar figure may no longer be relevant, the same logic may still be reasonably intact. At that time, he'd also pondered whether Mylan's failed attempt to acquire Perrigo in 2015-16 could be put back together given the troubles facing both companies. Gordon Haskett has flagged to investors that last night Perrigo postponed its investor event to discuss its long-term consumer growth strategies and key operational initiatives, previously planned as a conference call for September 25. Management had emphasized the event over 10 times on its earnings call just 3 weeks ago, the firm also noted.
08/28/18
HCWC
08/28/18
INITIATION
Target $28
HCWC
Buy
Coherus Biosciences initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Jason Kolbert started Coherus Biosciences (CHRS) with a Buy rating and $28 price target. The analyst expects approval of the company's Udencya in both the U.S. and Europe this year. His confidence level is driven by a positive recommendation from the European Committee for Medicinal Products for Human Use in July for marketing authorization of Udencya, a biosimilar compound targeting febrile neutropenia. Coherus announced that the committee reviewed all the new immunogenicity data that were required for the U.S. re-submission too, so the EU recommendation for approval adds a measure of confidence in support of U.S. approval, Kolbert tells investors in a research note. A year-end approval should position Udencya as the second biosimilar in the $4B U.S. marketplace behind Mylan (MYL), which should be launching its product following approval in June, the analyst adds.
AZN AstraZeneca
$37.49

-0.06 (-0.16%)

09/14/18
ROTH
09/14/18
NO CHANGE
Target $33
ROTH
Buy
Roth Capital remains bullish on Stemline after AstraZeneca's Lumoxiti approved
Roth Capital analyst Jotin Marango said he had viewed the BLA review for AstraZeneca's (AZN) Lumoxiti for Hairy Cell Leukemia as a relative gauge of what might happen with Stemline's (STML) Elzonris given what he sees as the similarities between the agents. Lumoxiti's approval makes him more bullish on Stemline ahead of the Q1 of 2019 PDUFA date for Elzonris, said Marango, who raised his assumed probability of success for its BLA to 90% from 75%. He raised his price target on Stemline shares to $33 from $30 and keeps a Buy rating on the stock.
09/17/18
PIPR
09/17/18
NO CHANGE
Target $35
PIPR
Neutral
Piper sees Astra's Lynparza as 'much cleaner' than Tesaro's Zejula
Piper Jaffray analyst Christopher Raymond reiterates a Neutral rating and $35 price target on Tesaro (TSRO) after analyzing a year's worth of adverse event reporting as captured by FDA's Adverse Event Reporting System database, which he obtained through a Freedom of Information Act request. The analyst, while cautioning that the database "likely contains inaccuracies and is far from perfect," is "struck by how much cleaner" AstraZeneca's (AZN) Lynparza appears versus Tesaro's Zejula and Clovis Oncology's (CLVS) Rubraca. Further, Raymond is also surprised that Zejula's adverse events rates do not appear to have decreased in any meaningful way year-over-year, despite Tesaro's active down-dosing efforts. Since the analyst thinks PARPi differentiation remains largely around safety, he lowered his Zejula estimates in 2019 and beyond. Lynparza is likely to maintain the upper hand, Raymond tells investors in a research note.
09/06/18
HCWC
09/06/18
NO CHANGE
Target $11
HCWC
Buy
H.C. Wainwright impressed by Checkpoint Therapeutics' first clinical data
H.C. Wainwright analyst Joseph Pantginis says Checkpoint Therapeutics' (CKPT) first clinical data in its history "did not disappoint." The data show a "significant clinical benefit" from CK-101 treatment, Pantginis tells investors in a research note. With these safety and efficacy data in hand, Checkpoint's CK-101 may show competitive clinical advantages versus approved EGFR therapies, including AstraZeneca's Tagrisso, at least in the non-small-cell lung carcinoma indication, the analyst contends. He's "impressed" with the data and notes that Checkpoint management has confirmed its intention to move into a pivotal study in 2019 mimicking the Tagrisso Flaura study. Pantginis has a Buy rating on Checkpoint Therapeutics with an $11 price target.
09/05/18
PIPR
09/05/18
NO CHANGE
Target $48
PIPR
Overweight
Biohaven deal with AstraZeneca enhances leadership, says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren says Biohaven Pharmaceutical (BHVN) has licensed a Phase III-ready central nervous system asset from AstraZeneca (AZN) that appears to have $500M-plus potential and "further broadens the company's pipeline." Based on his follow-up with management, the analyst believes the upfront cash payment is modest and that the Phase III trial will be efficient and require an estimated additional spend of $20M. Van Buren thinks the deal is an "attractively structured, efficient and opportunistic" that enhances Biohaven's leadership in CNS drug development. He keeps an Overweight rating on the shares with a $48 price target.
BDX Becton Dickinson
$259.79

2.54 (0.99%)

09/06/18
WELS
09/06/18
NO CHANGE
Target $290
WELS
Outperform
Becton Dickinson price target raised to $290 form $275 at Wells Fargo
Wells Fargo analyst Larry Biegelsen raised his price target for Becton Dickinson to $290 from $275 based on a blend of P/E and EV/EBITDA multiples to reflect increased peer group valuation. After hosting the company's management, the analyst believes that it has a good line of sight into key businesses and is confident in delivering 7% top-line growth in Q4. Biegelsen reiterates an Outperform rating on the shares.
06/21/18
JPMS
06/21/18
UPGRADE
Target $275
JPMS
Overweight
Becton Dickinson upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Robbie Marcus upgraded Becton Dickinson to Overweight and raised his price target for the shares to $275 from $250. The analyst sees a "clear path" for Becton to exceed expectations for the second half of 2018 and fiscal 2019 now that the Bard acquisition is two quarters in. With sustainable 5% organic sales growth, a minimum of low-double-digit earnings growth "arguably a given for the foreseeable future," and sustainable 90% free cash flow conversion, Becton deserves a premium multiple even after factoring in its leverage, Marcus tells investors in a research note.
09/10/18
ADAM
09/10/18
NO CHANGE
Target $80
ADAM
Buy
Quidel could draw interest from a larger company, says Canaccord
Canaccord analyst Mark Massaro remains positive on Quidel (QDEL) after hosting meetings with management. The analyst cited rising demand for its new products and he expects the company to continue to take market share from larger companies Alere (ABT) and Becton Dickinson (BDX). He also believes the company could draw interest from a larger company, like the bid Alere got from Abbott. Massaro reiterated his Buy rating and raised his price target to $80 from $78 on Quidel shares.
06/21/18
06/21/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. PayPal (PYPL) upgraded to Overweight from Neutral at Atlantic Equities with analyst Kunaal Malde saying he believes the company's differentiated checkout experience should enable the company to continue taking share. 2. Verizon (VZ) and Charter (CHTR) were upgraded to Buy from Neutral at Goldman Sachs. 3. Terex (TEX) upgraded to Buy from Hold at Jefferies with analyst Stephen Volkmann saying Terex has underperformed both the S&P 500 Index and machinery peers year-to-date despite improving backlog and visibility into 2019. 4. AMC Entertainment (AMC) upgraded to Buy from Hold at Benchmark with analyst Mike Hickey saying he believes the company's new movie subscription service will succeed in driving incremental attendance and EBITDA. 5. Becton Dickinson (BDX) upgraded to Overweight from Neutral at JPMorgan with analyst Robbie Marcus saying he sees a "clear path" for Becton to exceed expectations for the second half of 2018 and fiscal 2019 now that the Bard acquisition is two quarters in. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
BIIB Biogen
$337.01

2.65 (0.79%)

09/17/18
OPCO
09/17/18
NO CHANGE
Target $400
OPCO
Outperform
Roche's AD updates provide favorable read-through for Biogen, says Oppenheimer
Oppenheimer analyst Jay Olson says he remain bullish on Biogen (BIIB), telling investors in a research note that he believes Roche's (RHHBY) Alzheimer's disease updates provide a favorable read-through for Biogen's own Alzheimer's disease portfolio. Among the takeaways from Roche's pipeline update are the importance of a reduction in amyloid, confidence in dose escalation, epidemiology estimate and reimbursement commentary. Olson, who has an Outperform rating and $400 price target on Biogen, says he believes shares are undervalued based on his view that the company's leadership position in neuroscience should deliver long-term growth.
08/28/18
PIPR
08/28/18
NO CHANGE
PIPR
Overweight
Piper says Biogen PRIME data has little to change minds of bulls or bears
After Biogen (BIIB) and Eisai (ESALY) announced another year's worth of long term extension data from their ongoing PRIME Phase 1b study of aducanumab, Piper Jaffray analyst Christopher Raymond said he sees little in the release to change the minds of either A-beta bulls or A-beta bears. Raymond, who continues to look toward a full Phase 3 data read-out in early 2020 as the key event for aducanumab, keeps an Overweight rating on Biogen shares.
08/07/18
STFL
08/07/18
INITIATION
Target $48
STFL
Hold
Ionis Pharmaceuticals transferred with a Hold at Stifel
Stifel transferred coverage of Ionis Pharmaceuticals (IONS) to analyst Paul Matteis, who set a Hold rating and $48 price target on the shares. The Biogen (BIIB) deal, while validating, limits some of the future upside for Ionis, Matteis tells investors. Also, despite his long-term bullishness on the TTR amyloidisis opportunity, he is below consensus for the first year of the launches for Tegsedi and Waylivra.
08/07/18
STFL
08/07/18
INITIATION
Target $394
STFL
Biogen resumed with a Buy at Stifel
Stifel analyst Paul Matteis resumed coverage of Biogen with a Buy rating and a $394 price target, citing his above consensus projections for Spinraza in Spinal Muscular Atrophy and his view that the odds of success for Aducanumab in Alzheimer's are "modestly better than 50/50." While there are real reasons to believe "this time is different" with Aducanumab, Matteis does worry that the floor value in a negative scenario for the Alzheimer's drug might be lower than some think, he tells investors.
BSX Boston Scientific
$37.63

0.36 (0.97%)

09/04/18
09/04/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. UPS (UPS) upgraded to Strong Buy from Market Perform at Raymond James with analyst Patrick Tyler Brown saying he believes investors are underappreciating UPS' long-term Domestic EBIT and 2021 free cash flow outlook, which could be greater than $8B. 2. Qualcomm (QCOM) upgraded to Outperform from Neutral at Macquarie with analyst Srini Pajjuri saying he believes risk/reward is attractive and sees multiple catalysts ahead including a final settlement with Huawei in the near future, increasing probability of an Apple (AAPL) settlement, and a 5G cycle that is not fully reflected in consensus estimates. 3. Albemarle (ALB) upgraded to Buy from Hold at SunTrust with analyst James Sheehan saying investors have driven down the price of the stock amid lithium oversupply concern on incorrect assumption that it is a commodity. 4. Univar (UNVR) upgraded to Buy from Hold at Berenberg with analyst Thomas Burlton saying the company is improving its conversion margin and EBITDA growth while its cash generation is also getting better. 5. Boston Scientific (BSX) upgraded to Buy from Hold at Jefferies with analyst Raj Denhoy citing a survey of 25 U.S. transcatheter aortic valve replacement doctors to gauge interest in tBoston Scientific's Lotus value. While feedback was better for Edwards Lifesciences (EW) and Medtronic's (MDT) valves, the majority of respondents were still interested in trying Lotus and expected the valve to capture 16%-18% share of the market. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/10/18
NEED
09/10/18
NO CHANGE
Target $43
NEED
Strong Buy
Boston Scientific price target raised to $43 from $39 at Needham
Needham analyst Mike Matson raised his price target on Boston Scientific to $43 and kept his Strong Buy rating. The analyst cites the company's latest $500M bid Augmenix, whose SpaceOAR reduces side effects associated with prostate radiotherapy. While the company expects "immaterial" earnings impact from the deal through 2019, Matson believes that it will strengthen its Urology & Pelvic Health business longer term, with added potential "revenue synergies given BSX's NxThera acquisition and legacy GreenLight XPS system".
09/04/18
JEFF
09/04/18
UPGRADE
Target $42
JEFF
Buy
Jefferies upgrades Boston Scientific to Buy after TAVR doctor survey
Jefferies analyst Raj Denhoy upgraded Boston Scientific (BSX) to Buy from Hold and raised his price target for the shares to $42 from $34. He upgraded the shares after surveying 25 U.S. transcatheter aortic valve replacement doctors to gauge interest in tBoston Scientific's Lotus value. While feedback was better for Edwards Lifesciences (EW) and Medtronic's (MDT) valves, the majority of respondents were still interested in trying Lotus and expected the valve to capture 16%-18% share of the market, Denhoy tells investors in a research note. He notes that by 2022, the U.S. TAVR market is expected to be $3.1B and the global market $6.5B. Boston Scientific's revenue growth can be sustained at 7% through at least 2022, Denhoy writes. That level of growth keeps Boston Scientific at the upper end of medtech growth and supports a positive view on the stock, the analyst adds.
09/05/18
ARGS
09/05/18
NO CHANGE
Target $41
ARGS
Buy
Boston Scientific price target raised to $41 from $36 at Argus
Argus analyst Jasper Hellweg raised his price target on Boston Scientific to $41 and kept his Buy rating, saying the company's outperformance over the past 3 months has been driven by its new product and acquisition news. Hellweg further cites the company's Q2 results showing organic sales growth up in all 3 of its sectors and across all regions. The analyst also notes that the stock price is trading in a bullish pattern of higher lows and highs going back to 2012 and believes that Boston Scientific is deserving of its premium valuation based on its growth outlook and profitability profile.
GLPG Galapagos NV
$116.56

0.81 (0.70%)

08/09/18
08/09/18
DOWNGRADE

Neutral
Galapagos NV downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs analyst Keyur Parekh downgraded Galapagos NV to Neutral from Buy, saying he sees a more balanced risk-reward profile for the stock after its 10% outperformance relative to the Dow Jones STOXX Healthcare index SXDP. The analyst also points to the company's disappointing Cystic Fibrosis update on June 28th while looking ahead to the late-stage readouts for filgotinib's FINCH2 trial in rheumatoid arthritis and TORTUGA trial in ankylosing spondylitis in Q3 of this year.
09/13/18
JPMS
09/13/18
INITIATION
Target $140
JPMS
Overweight
Galapagos NV initiated with an Overweight at JPMorgan
JPMorgan analyst James Quigley started Galapagos NV (GLPG) with an Overweight rating and $140 price target. The company's key value driver is filgotinib, a selective JAK1 inhibitor which has shown potential best in class data in inflammatory diseases and is licensed to Gilead (GILD), Quigley tells investors in a research note. The analyst forecasts peak in market filgotinib sales of EUR 4.4B. Quigley also sees value in Galapagos' wholly owned GLPG1690, which he says could be the first drug to halt disease progression in idiopathic pulmonary fibrosis.
09/12/18
JPMS
09/12/18
INITIATION
JPMS
Overweight
Galapagos NV initiated with an Overweight at JPMorgan
09/12/18
NOMU
09/12/18
NO CHANGE
Target $124
NOMU
Buy
Galapagos data meets expectations 'and then some,' says Nomura Instinet
Nomura Instinet analyst Christopher Marai says Galapagos NV (GLPG) and Gilead's (GILD) positive top-line results from the Finch-2 study evaluating filgotinib in moderate-to-severe rheumatoid arthritis patients met his expectations "and then some." The anlayst keeps a Buy rating on Galapagos with a $124 price target.
GSK GlaxoSmithKline
$39.62

0.415 (1.06%)

07/25/18
WELS
07/25/18
NO CHANGE
WELS
Market Perform
Even minor delays can hurt Mylan's generic Advair opportunity, says Wells Fargo
After GlaxoSmithKline (GSK) reported U.S. Advair sales declined 43% at constant currency in Q2, Wells Fargo analyst David Maris commented on the read-through to the generic Advair opportunity being pursued by Mylan (MYL). Given the substantial declines branded Advair faces, he said that "even minor delays" can continue to hurt the potential generic opportunity, adding that he has not seen or been notified of any updates from Mylan on Advair since the company was notified in early June that the FDA planned to issue an official Complete Response Letter related to its application. Maris keeps a Market Perform rating on Mylan shares.
08/15/18
RBCM
08/15/18
NO CHANGE
RBCM
Outperform
RBC says Gilead weakness on CMO leaving, Glaxo data a buying opportunity
RBC Capital analyst Brian Abrahams believes Gilead's (GILD) weakness is potentially due to data from GlaxoSmithKline's (GSK) ATLAS trial and last night's announcement of the departure of its CMO. However, he does not see either as a major fundamental concern and would use the weakness in Gilead shares as a buying opportunity. Feedback he has received from doctors is that injectables like Glaxo's could be used in a select number of patients, but he does not see a major impact on Gilead's HIV franchise near- or long-term from this product, Abrahams said. On the CMO departure, the analyst said that the company clarified that this is "completely unrelated" to the recently-announced CEO transition, so he does not see this reflecting any major structural issue. Abrahams keeps an Outperform rating on Gilead shares, which are down over 3% to $74.82 in afternoon trading.
08/16/18
08/16/18
DOWNGRADE

Hold
AstraZeneca downgraded to Hold following outperformance at Jefferies
As previously reported, Jefferies analyst Ian Hilliker downgraded AstraZeneca (AZN) to Hold from Buy citing valuation following the stock's outperformance since he upgraded it in March. Hilliker has raised his price target on AstraZeneca to 6,200p, but notes that this only leaves about 8% of further upside. Following results for the Q2 period, Hilliker said Novartis (NVS) remains his top European Pharmaceuticals pick, followed by Roche (RHHBY) and GlaxoSmithKline (GSK) in third place.
08/30/18
08/30/18
DOWNGRADE

GlaxoSmithKline downgraded to Hold from Buy at Liberum
Liberum analyst Roger Franklin downgraded GlaxoSmithKline to Hold while raising his price target for the shares to GBP 17 from GBP 16.30. The analyst believes the company's improved research and development is now priced into the shares and he sees less upside going forward.
MMM 3M
$211.54

1.99 (0.95%)

07/31/18
ARGS
07/31/18
NO CHANGE
Target $240
ARGS
Buy
3M offers attractive entry point, says Argus
Argus analyst John Eade kept his Buy rating and $240 price target on 3M, saying the stock trades at an "attractive" valuation for an entry point based on its recent Q2 earnings beat, continued double-digit growth expectations through 2019, and only a 3% rise in price over the past year. Eade further points to 3M's margin expansion and share buyback program, which have the potential to drive double-digit earnings growth over the course of a 5-year business cycle. The analyst also believes that "3M should get an earnings boost from improving global economic conditions and a stable-to-weaker dollar in 2018-2019", as well as from its focus on innovation leading to development of new products.
09/14/18
TIGR
09/14/18
NO CHANGE
TIGR
Buy
3M accelerating performance with organic growth, says Tigress Financial
Tigress Financial analyst Ivan Feinseth keeps his Buy rating on 3M, saying the company continues to accelerate its business performance with "organic growth across all business segments and geographic regions". He sees "strong demand" across the product lines and sound management of a vast portfolio. The analyst is also positive on the company's capital return program and its growth oriented M&A and R&D strategies.
08/20/18
MSCO
08/20/18
INITIATION
Target $212
MSCO
Equal Weight
3M initiated with an Equal Weight at Morgan Stanley
Morgan Stanley analyst Joshua Pokrzywinski initiated 3M with an Equal Weight rating and a price target of $212. The analyst notes that the company has managed risks appropriately to prepare for a potential 2019 slowdown across the industrials, but adds that its valuation still puts it at only a modest peer group relative discount from the historical perspective, stating that there is little upside to valuation from the stock's current levels.
07/12/18
DBAB
07/12/18
DOWNGRADE
Target $208
DBAB
Hold
3M resumed with a Hold from Buy at Deutsche Bank
Deutsche Bank analyst Nicole DeBlase resumed coverage of 3M with a Hold rating and $208 price target, a downgrade from her firm's prior Buy rating. The analyst is "relatively cautious on short-cycle industrials," saying the second derivative of growth is turning negative.
MDT Medtronic
$96.91

0.91 (0.95%)

09/05/18
OPCO
09/05/18
NO CHANGE
Target $54
OPCO
Outperform
Tandem Diabetes price target raised to $54 from $38 at Oppenheimer
Oppenheimer analyst Steven Lichtman raised his price target for Tandem Diabetes (TNDM) to $54 from $38 on updated market estimates. The analyst notes that Medtronic's (MDT) recently reported Q1 diabetes results combined with the Q2 performances from Tandem as well as Insulet (PODD) suggests a strong underlying U.S. insulin pump market. Lichtman is raising his U.S. insulin market growth outlook from high-single digits to low-double digits in 2019/2020. He believes Tandem is well suited to capture the benefits of this acceleration given its pipeline. Lichtman reiterates an Outperform rating on Tandem's shares.
09/13/18
PIPR
09/13/18
NO CHANGE
Target $58
PIPR
Overweight
Globus Medical Nemaris acquisition to be modest contributor, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien kept his Overweight rating and $58 price target on Globus Medical (GMED), saying the company's acquisition of Nemaris announced earlier today should be a "modest revenue contributor". The analyst estimates the price tag around $20M. Longer term, the analyst expects Nemaris' marketed Surgimap to bring help to the company in terms of staying ahead of Medtronic (MDT) in the surgical planning category.
09/05/18
PIPR
09/05/18
NO CHANGE
Target $150
PIPR
Overweight
Piper says investors need exposure to CGM market, prefers DexCom
The strong growth of the continuous glucose monitoring market seen in Q2 will continue for the next several years as CGM pushes towards standard of care in Type 1 diabetes and shows healthy adoption from insulin using Type 2s, Piper Jaffray analyst JP McKim tells investors in a research note. For mass adoption, pricing will need to come down, but even at $3-$4 per day in developed markets CGM is still an $80B worldwide addressable market, the analyst says. He thinks investors "need to have exposure" to the CGM market, and DexCom (DXCM) remains his favorite way to play the space. McKim keeps an Overweight rating on the shares with a $150 price target. He points out that Abbott (ABT), Dexcom and even Medtronic (MDT) posted CGM numbers in Q2 that were much better than expected.
NVS Novartis
$85.03

-0.1 (-0.12%)

09/11/18
09/11/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Nike (NKE) upgraded to Buy from Hold at Canaccord with analyst Camilo Lyon saying he believes Nike has regained its footing and is marching back to form following two years of a soft product cycle, margin compression, and market share declines. 2. Novartis (NVS) upgraded to Buy from Neutral at Citi and to Neutral from Underperform at Exane BNP Paribas. 3. Darden (DRI) upgraded to Buy from Neutral at Goldman Sachs while Bloomin' Brands (BLMN) was upgraded to Neutral from Sell. 4. South Jersey Industries (SJI) upgraded to Overweight from Neutral at JPMorgan with analyst Christopher Turnure saying the company's "superior" growth potential is coming into focus while its shares trade at a discount to peers. 5. Snap (SNAP) upgraded to Outperform from Neutral at Wedbush with analyst Michael Pachter noting that decelerating growth trends, fierce competition for user mindshare and advertiser dollars, and a history of being hugely unprofitable have kept him on the sidelines, but recent management changes and improved execution have led him to update his outlook. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/11/18
EXAN
09/11/18
UPGRADE
EXAN
Neutral
Novartis upgraded to Neutral from Underperform at Exane BNP Paribas
09/17/18
FBCO
09/17/18
NO CHANGE
Target $26
FBCO
Neutral
Teva price target raised to $26 from $23 at Credit Suisse
Credit Suisse analyst Vamil Divan reiterated a Neutral rating on Teva Pharmaceutical (TEVA) and raised his price target to $26 after the company said it received FDA approval for Ajovy, a key pipeline drug for migraine prevention and approval of a quarterly dosing for the drug, providing an important point of differentiation relative to competitors from Eli Lilly (LLY) and Amgen (AMGN)/Novartis (NVS). In a research note to investors, Divan says Friday's approval provides Teva with an important potential growth driver as it looks to overcome the challenges it faces with U.S. generics, Copaxone and its large debt load, and expects a "strong" positive reaction in the stock. Divan says he will look to see how Teva commercializes Ajovy in the coming months before becoming more constructive on the stock's longer-term outlook.
09/11/18
SBSH
09/11/18
UPGRADE
SBSH
Buy
Novartis upgraded to Buy from Neutral at Citi
Citi upgraded Novartis to Buy from Neutral. Exane BNP Paribas also upgraded the shares this morning to Neutral.
ORN Orion Group
$8.10

0.28 (3.58%)

11/08/17
ADAM
11/08/17
UPGRADE
ADAM
Buy
Orion Group upgraded to Buy from Hold at Canaccord
01/25/18
NBLE
01/25/18
INITIATION
Target $10
NBLE
Buy
Orion Group initiated with a Buy at Noble Financial
Noble Financial analyst Ben Kileve initiated Orion Group with a Buy and $10 price target saying he sees further share upside from healthy end markets, record levels of bids outstanding and from the launching of the high ceiling Industrial segment.
PHG Philips
$45.49

0.11 (0.24%)

09/13/18
BERN
09/13/18
INITIATION
BERN
Outperform
Philips initiated with an Outperform at Bernstein
Bernstein analyst Lisa Bedell Clive started Philips with an Outperform rating, saying the company is nearing completion of a long-term transition, as it has pivoted from its industrial roots to become a healthcare equipment and IT company. The analyst adds that in recent years, the R&D division has taken Philips' portfolio of medical equipment and home-based patient monitoring devices to the next level, with a focus on better inter-connectivity and the integration of data analytics, including the growing use of Artificial Intelligence.
04/17/18
DBAB
04/17/18
UPGRADE
DBAB
Buy
Philips upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank upgraded Philips to Buy from Hold.
09/17/18
EXAN
09/17/18
UPGRADE
EXAN
Outperform
Philips upgraded to Outperform from Neutral at Exane BNP Paribas
07/23/18
DBAB
07/23/18
NO CHANGE
DBAB
Philips named a Catalyst Buy at Deutsche Bank
PKI PerkinElmer
$94.89

0.305 (0.32%)

09/05/18
09/05/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Anthem (ANTM) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Zack Sopcak saying he contends that the disruption in the pharmacy benefits management landscape via M&A and government-led drug pricing reform positions Anthem for underappreciated share gain and accelerated profit growth. 2. BP (BP) upgraded to Overweight from Equal Weight at Morgan Stanley. 3. GasLog (GLOG) upgraded to Buy from Hold at DNB Markets. 4. CenterPoint Energy (CNP) upgraded to Overweight from Neutral at JPMorgan with analyst Christopher Turnure saying he sees an "attractive outlook for the proforma company" with 8.2% annual earnings growth through 2021 "under a conservative range of assumptions." 5. PerkinElmer (PKI) upgraded to Equal Weight from Underweight at Barclays with analyst Jack Meehan saying he is more positive on PerkinElmer's near-term growth prospects in Diagnostics due to its recent investments. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/05/18
LEHM
09/05/18
UPGRADE
Target $90
LEHM
Equal Weight
Barclays upgrades PerkinElmer to Equal Weight with $90 target
Barclays analyst Jack Meehan upgraded PerkinElmer (PKI) to Equal Weight from Underweight and raised his price target for the shares to $90 from $79. The analyst is more positive on PerkinElmer's near-term growth prospects in Diagnostics due to its recent investments. Combined with margin expansion and capital deployment, he thinks PerkinElmer is better positioned to drive low-to-mid teens earnings growth. Meehan this morning also downgraded Hologic (HOLX) to Equal Weight and Myriad Genetics (MYGN) to Underweight.
09/05/18
LEHM
09/05/18
UPGRADE
Target $90
LEHM
Equal Weight
PerkinElmer upgraded to Equal Weight from Underweight at Barclays
Barclays analyst Jack Meehan upgraded PerkinElmer to Equal Weight and raised his price target for the shares to $90 from $79.
08/30/18
CLVD
08/30/18
UPGRADE
CLVD
Buy
PerkinElmer upgraded to Buy from Neutral at Cleveland Research
REGN Regeneron
$388.02

1.5 (0.39%)

08/08/18
PIPR
08/08/18
NO CHANGE
PIPR
Overweight
Piper says CMS Part B headlines 'scary,' but Regeneron pullback an overreaction
Piper Jaffray analyst Christopher Raymond said he would be a buyer on weakness in shares of Regeneron after CMS announced new rules giving Medicare Advantage plans the option of implementing "step therapy" to introduce competition. He checked in with leading drug pricing and reimbursement experts, whose view is that this may drive discounting and competition between Eylea and Lucentis, much like what exists today with private pay plans. After speaking with management, Raymond estimates about 3.4% of 2019 Eylea revenue is at risk. Assuming Regeneron has to price at Eylea at a 30% discount translates to a roughly $40M revenue impact and a 36c, or 1.5%, hit to EPS in 2019, said Raymond, who called the 6% pullback in the stock an overreaction in light of those estimates. He maintains an Overweight rating on Regeneron shares.
08/16/18
PIPR
08/16/18
NO CHANGE
Target $450
PIPR
Overweight
Regeneron's fasinumab safety remains 'open question,' says Piper Jaffray
Piper Jaffray analyst Christopher Raymond backed an Overweight rating on Regeneron Pharmaceuticals (REGN) shares following this morning's release of fasinumab results, saying the drug and partner Teva's (TEVA) anti-NGF antibody met its primary and secondary efficacy pain and functional endpoints in a Phase 3 trial of patients with chronic pain from osteoarthritis of the knee or hip. Raymond says the efficacy "was never really in doubt," but the bigger focus for the drug is safety, and will wait for detailed data at an upcoming medical meeting, but notes that fasinumab's arthropathy rate appears "slightly higher" than that of tanezumab. Given the severity of the ongoing opioid epidemic and relative lack of alternatives for these patients outside of total joint replacement, the analyst thinks the appetite of regulators and potential market for new effective, non-opioid chronic pain therapies like anti-NGF clearly exists, though he will leave this as an unmodeled potential source of upside for now,
09/13/18
STFL
09/13/18
INITIATION
Target $127
STFL
Buy
AnaptysBio resumed with a Buy at Stifel
Stifel analyst Derek Archila resumed coverage of AnaptysBio (ANAB) with a Buy rating and $127 price target, stating that he is positively biased heading into etokimab's Phase 2a results for severe eosinophilic asthma, given his view on the strong rationale for the inhibition of IL-33, etokimab's meaningful reduction of eosinophils seen in an earlier Phase 2a study, and the success of Regeneron (REGN) and Sanofi's (SNY) Dupixent.
08/13/18
PIPR
08/13/18
NO CHANGE
PIPR
Overweight
Regeneron should be bought on 'largely meaningless' CRL, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond recommends buying shares of Regeneron Pharmaceuticals on weakness after the company received a Complete Response Letter from the FDA regarding Eylea's supplemental Biologics License Application for Q12W dosing in wet macular degeneration. The CRL is "largely meaningless" as this label expansion is almost entirely a defensive move by Regeneron to counter potential Q12W labeling by competitor Novartis' (NVS) RTH258, Raymond tells investors in a research note. The analyst has "reasonable confidence" that approval for this label will come within two months. He keeps an Overweight rating on shares of Regeneron.
RMD ResMed
$113.48

0.71 (0.63%)

09/10/18
NEED
09/10/18
DOWNGRADE
Target $296
NEED
Buy
Inogen downgraded to Buy from Strong Buy at Needham
Needham analyst Mike Matson downgraded Inogen (INGN) to Buy from Strong Buy but raised his price target to $296 from $254. The analyst cites the potential for slower growth as tougher comps start in the second half of 2018, along with a tighter level of competition from Resmed (RMD) and valuation following the 122% year-to-date run-up in the stock price. Matson adds that while Inogen is no longer a "top pick" in his space, he still sees it as a "premier growth story" positioned to produce upside to consensus
05/31/18
05/31/18
NO CHANGE

Arcturus Therapeutics reinstates founder Joseph Payne as CEO
Arcturus Therapeutics (ARCT) has named Dr. Peter Farrell as Chairman of the Board of Directors of the company. Joseph E. Payne has been reinstated as President and CEO and Dr. Pad Chivukula has been reinstated as Chief Scientific Officer and COO. Peter Farrell is the founder, former long-term CEO and current Chairman of ResMed (RMD).
07/01/18
GSCO
07/01/18
INITIATION
GSCO
Buy
ResMed initiated with a Buy at Goldman Sachs
05/30/18
PIPR
05/30/18
NO CHANGE
Target $190
PIPR
Overweight
Inogen recent pullback a buying opportunity, says Piper Jaffray
Piper Jaffray analyst JP McKim views the recent pullback in shares of Inogen (INGN) as unwarranted and recommends buying the shares at current levels. The analyst says his firm's survey of 66 home medical equipment providers indicates the shift to portable oxygen concentrators "remains strong." The market remains in the early innings of this conversion and Inogen is the best way to play this thematic trend, McKim tells investors in a research note. The analyst expects ResMed's (RMD) Mobi to launch this year, but does not expect it to be overly impactful to Inogen. Consensus numbers already reflect a deceleration in growth in the second half of 2018 which is unlikely to materialize, McKim contends. He keeps an Overweight rating on Inogen with a $190 price target.
SNY Sanofi
$43.96

0.17 (0.39%)

09/14/18
LSCM
09/14/18
NO CHANGE
Target $90
LSCM
Buy
Apple Watch more likely a positive for BioTelemetry, says Lake Street
After spending time with Joe Capper and Heather Getz, CEO and CFO of BioTelemetry (BEAT), Lake Street analyst Brooks O'Neil senses that Apple's (AAPL) Watch Series 4, which includes a built-in electrocardiogram, is more likely a positive for BioTelemetry "than a buzzer sounding a flat-line for the company's future." BioTelemetry remains the leading cardiac monitoring company and this is likely to continue for the foreseeable future, O'Neil tells investors in a research note. He points out the company has a partnership with Apple in cardiac monitoring and with Sanofi (SNY) and Alphabet (GOOG) in diabetes. The analyst's guesses that its partnership is one element giving BioTelemetry management comfort in evaluating the role Apple might play in the company's future. O'Neil reaffirms a Buy rating on the shares with a $90 price target.
09/10/18
BOFA
09/10/18
UPGRADE
BOFA
Buy
Sanofi upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst Graham Parry upgraded Sanofi to Buy from Neutral saying the company is approaching an inflection in growth from new products, mainly Dupixent, atopic, dermatitis, while diabetes becomes less of a headwind. Parry believes sales and earnings growth will accelerate to 7% from 4% in through 20-2023E and views valuation as undervaluing growth.
09/10/18
MSCO
09/10/18
INITIATION
Target $72
MSCO
Overweight
MyoKardia initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst Jeffrey Hung initiated MyoKardia (MYOK) at Overweight with a $72 price target, stating that the obstructive hypertrophic cardiomyopathy Phase 2 data for its lead program, mavacamten, were "robust" and the fact that the company is partnered with Sanofi (SNY) gives him incremental confidence. He expects a mavacamten launch in oHCM in early 2022 and peak U.S. sales for the drug of greater than $1.3B.
TEVA Teva
$24.50

1.06 (4.52%)

09/17/18
BTIG
09/17/18
UPGRADE
BTIG
Neutral
Teva upgraded to Neutral from Sell at BTIG
BTIG analyst Timothy Chiang upgraded Teva to Neutral from Sell, citing the positive impact of the FDA approval for Ajovy in the prevention of episodic and chronic migraines. The analyst believes that the drug has the potential to become a "blockbuster product by 2022 with estimated sales of about $1B". Chiang further notes that the approval comes at a "critical" point for the new CEO Schultz as he leads a turnaround of the company, adding that the product label and a potential differentiation relative to other CGRP-antagonists will be key for Ajovy. The analyst models Ajovy sales reaching $500M in 2020.
09/17/18
WELS
09/17/18
NO CHANGE
Target $23
WELS
Market Perform
Migraine drug approval an 'important win' for Teva, says Wells Fargo
Wells Fargo analyst David Maris called news that the FDA has Teva's anti-CGRP treatment for the prevention of migraine an "important win" for the company given its lack of other near-term pipeline assets and continuing troubles in generics. Maris, who said not all investors thought Teva would get the approval given there was a previous setback, estimates 2018 North America sales of Ajovy of $10M and 2019 North America sales of $116M. He maintains a Market Perform rating and $23 price target on Teva shares.
09/17/18
09/17/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Teva (TEVA) upgraded to Neutral from Sell at BTIG with analyst Timothy Chiang citing the positive impact of the FDA approval for Ajovy in the prevention of episodic and chronic migraines. 2. American Express (AXP) upgraded to Overweight from Equal Weight at Stephens with analyst Vincent Caintic saying the company is successfully monetizing its card network by increasing merchant engagement to drive higher billed business volumes. 3. Lululemon (LULU) upgraded to Outperform from Market Perform at Wells Fargo with analyst Ike Boruchow saying while the brand's current strength is "evident to essentially everyone," his recent meetings with management lead him to believe that its "industry leading" momentum is likely sustainable through the second half of this year and well into 2019. 4. Broadcom (AVGO) upgraded to Buy from Neutral at Nomura Instinet with analyst Romit Shah saying "so many positive takeaways from earnings" has forced him to take a more constructive stance on the shares. 5. MasterCard (MA) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst James Schneider saying he continues to see upside to consensus estimates over the next 12 months driven by core consumer volume and exposure to Europe and other growth markets. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

CMCSA

Comcast

$37.91

0.1 (0.26%)

, CMCSK

Comcast

$0.00

(0.00%)

14:32
09/22/18
09/22
14:32
09/22/18
14:32
Periodicals
Comcast outbids Fox in battle for Sky, Reuters reports »

Comcast (CMCSA; CMCSK)…

CMCSA

Comcast

$37.91

0.1 (0.26%)

CMCSK

Comcast

$0.00

(0.00%)

FOX

21st Century Fox

$43.97

-0.23 (-0.52%)

FOXA

21st Century Fox

$44.33

-0.26 (-0.58%)

SKYAY

Sky

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BOKF

BOK Financial

$104.69

-0.08 (-0.08%)

, COBZ

CoBiz Financial

$23.44

0.01 (0.04%)

13:36
09/22/18
09/22
13:36
09/22/18
13:36
Conference/Events
CoBiz Financial to host special shareholder meeting »

Special Shareholder…

BOKF

BOK Financial

$104.69

-0.08 (-0.08%)

COBZ

CoBiz Financial

$23.44

0.01 (0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 27

    Sep

AMRH

AMERI Holdings

$1.44

-0.04 (-2.70%)

13:30
09/22/18
09/22
13:30
09/22/18
13:30
Conference/Events
AMERI Holdings to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

BRK.A

Berkshire Hathaway

$331,710.00

-1090 (-0.33%)

13:26
09/22/18
09/22
13:26
09/22/18
13:26
Periodicals
Berkshire Hathaway still looks underpriced, Barron's says »

Class A shares of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLGO

BioLargo

$0.00

(0.00%)

13:11
09/22/18
09/22
13:11
09/22/18
13:11
Conference/Events
BioLargo to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CZWI

Citizens Community Bancorp

$14.13

0.03 (0.21%)

12:56
09/22/18
09/22
12:56
09/22/18
12:56
Conference/Events
Citizens Community Bancorp to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SF

Stifel Financial

$54.86

-0.78 (-1.40%)

12:50
09/22/18
09/22
12:50
09/22/18
12:50
Conference/Events
Stifel Financial to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBCT

People's United

$17.94

-0.055 (-0.31%)

, FBNK

First Connecticut

$30.95

0.1 (0.32%)

12:47
09/22/18
09/22
12:47
09/22/18
12:47
Conference/Events
First Connecticut to host special shareholder meeting »

Special shareholder…

PBCT

People's United

$17.94

-0.055 (-0.31%)

FBNK

First Connecticut

$30.95

0.1 (0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 18

    Oct

ASPS

Altisource

$34.10

-0.09 (-0.26%)

12:44
09/22/18
09/22
12:44
09/22/18
12:44
Conference/Events
Altisource to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$217.65

-2.35 (-1.07%)

, CSCO

Cisco

$48.51

0.77 (1.61%)

12:36
09/22/18
09/22
12:36
09/22/18
12:36
Periodicals
Apple, Microsoft among stocks with solid dividends, Barron's says »

Technology stocks are not…

AAPL

Apple

$217.65

-2.35 (-1.07%)

CSCO

Cisco

$48.51

0.77 (1.61%)

IBM

IBM

$151.29

0.12 (0.08%)

MSFT

Microsoft

$114.70

1.13 (0.99%)

ORCL

Oracle

$51.08

0.65 (1.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 25

    Sep

  • 26

    Sep

  • 26

    Sep

  • 26

    Sep

  • 27

    Sep

  • 03

    Oct

  • 04

    Oct

  • 05

    Oct

  • 10

    Oct

  • 21

    Oct

  • 22

    Oct

  • 22

    Oct

  • 24

    Oct

  • 25

    Oct

  • 28

    Oct

  • 28

    Nov

  • 03

    Mar

CAT

Caterpillar

$156.39

0.38 (0.24%)

, AMAT

Applied Materials

$39.62

0.22 (0.56%)

12:28
09/22/18
09/22
12:28
09/22/18
12:28
Periodicals
Caterpillar, KeyCorp among stocks to buy as bond yields rise, Barron's says »

As the economy improves,…

CAT

Caterpillar

$156.39

0.38 (0.24%)

AMAT

Applied Materials

$39.62

0.22 (0.56%)

BWA

BorgWarner

$45.24

-0.53 (-1.16%)

KEY

KeyCorp

$20.78

0.02 (0.10%)

PH

Parker-Hannifin

$190.52

0.01 (0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Sep

  • 18

    Oct

  • 25

    Oct

  • 30

    Oct

BSX

Boston Scientific

$37.76

-0.07 (-0.19%)

, ISRG

Intuitive Surgical

$556.70

-4.43 (-0.79%)

10:34
09/22/18
09/22
10:34
09/22/18
10:34
Periodicals
'Good time' to think about device markers, Barron's says »

Medical technology stocks…

BSX

Boston Scientific

$37.76

-0.07 (-0.19%)

ISRG

Intuitive Surgical

$556.70

-4.43 (-0.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Oct

TLRY

Tilray

$123.16

-53.365 (-30.23%)

10:20
09/22/18
09/22
10:20
09/22/18
10:20
Periodicals
Marijuana stocks 'the new Bitcoin,' Barron's says »

Led by Tilray, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$217.65

-2.35 (-1.07%)

, WMT

Walmart

$95.85

0.1 (0.10%)

09:05
09/22/18
09/22
09:05
09/22/18
09:05
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AAPL

Apple

$217.65

-2.35 (-1.07%)

WMT

Walmart

$95.85

0.1 (0.10%)

DE

Deere

$152.82

-1.24 (-0.80%)

AGCO

Agco

$60.24

-0.9 (-1.47%)

ADM

Archer Daniels

$50.33

(0.00%)

MOS

Mosaic

$32.33

0.02 (0.06%)

CF

CF Industries

$52.82

-0.48 (-0.90%)

SPWR

SunPower

$7.88

-0.18 (-2.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 28

    Oct

  • 06

    Nov

  • 13

    Nov

  • 15

    Nov

  • 03

    Mar

AERI

Aerie Pharmaceuticals

$58.50

0.1 (0.17%)

, AGN

Allergan

$191.34

-1.11 (-0.58%)

04:55
09/22/18
09/22
04:55
09/22/18
04:55
Conference/Events
European Society of Retina Specialists to hold a conference »

18th Congress of EURETINA…

AERI

Aerie Pharmaceuticals

$58.50

0.1 (0.17%)

AGN

Allergan

$191.34

-1.11 (-0.58%)

ALIM

Alimera Sciences

$1.07

(0.00%)

BABY

Natus Medical

$34.45

-0.2 (-0.58%)

BHC

Bausch Health

$24.92

-0.07 (-0.28%)

BAYRY

Bayer

$0.00

(0.00%)

ELXMF

Ellex Medical Lasers

$0.00

(0.00%)

GKOS

Glaukos

$58.78

-1.69 (-2.79%)

IRIX

IRIDEX

$6.52

0.08 (1.24%)

JNJ

Johnson & Johnson

$142.85

0.85 (0.60%)

NITE

Nightstar Therapeutics

$25.64

-1.71 (-6.25%)

NVS

Novartis

$85.46

-0.505 (-0.59%)

OCUL

Ocular Therapeutix

$6.45

0.03 (0.47%)

RHHBY

Roche

$0.00

(0.00%)

SHPG

Shire

$178.32

-1.68 (-0.93%)

STAA

STAAR Surgical

$47.00

-0.9 (-1.88%)

TMDI

Titan Medical

$2.24

0.02 (0.90%)

TTNP

Titan Pharmaceuticals

$0.22

-0.2833 (-56.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 24

    Sep

  • 25

    Sep

  • 27

    Sep

  • 01

    Oct

  • 03

    Oct

  • 09

    Oct

  • 16

    Oct

  • 22

    Oct

  • 28

    Oct

  • 29

    Oct

  • 15

    Nov

  • 27

    Nov

  • 21

    Dec

  • 28

    Dec

  • 15

    Feb

  • 25

    Feb

CDTI

CDTi

$0.34

0.01 (3.08%)

18:15
09/21/18
09/21
18:15
09/21/18
18:15
Hot Stocks
CDTi sees September 21 as effective date of reverse stock split »

CDTi Advanced Materials…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DUK

Duke Energy

$79.82

-0.81 (-1.00%)

18:08
09/21/18
09/21
18:08
09/21/18
18:08
Hot Stocks
Duke Energy restored nearly 1.8M outages in NC, SC during past week »

Duke Energy crews today…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 02

    Oct

  • 03

    Oct

  • 04

    Oct

  • 11

    Nov

JNJ

Johnson & Johnson

$142.85

0.85 (0.60%)

18:01
09/21/18
09/21
18:01
09/21/18
18:01
Hot Stocks
Johnson & Johnson's Janssen discloses phase 3 study results of Esketamine »

The Janssen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 28

    Oct

UAL

United Continental

$89.94

0.8 (0.90%)

17:39
09/21/18
09/21
17:39
09/21/18
17:39
Periodicals
United pilots refuse contract changes on regional routes, Reuters says »

United Airlines pilots…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

XLE

Energy Select Sector SPDR

$75.11

0.5132 (0.69%)

, XLU

Utilities SPDR

$53.04

0.2049 (0.39%)

17:36
09/21/18
09/21
17:36
09/21/18
17:36
General news
Week ending ETF Scorecard: Materials outperform, Utlilites slump »

S&P500 SECTORS:…

XLE

Energy Select Sector SPDR

$75.11

0.5132 (0.69%)

XLU

Utilities SPDR

$53.04

0.2049 (0.39%)

IYR

DJ US Real Estate Index Fund

$81.88

-0.06 (-0.07%)

XLP

Consumer Staples Sector SPDR

$55.02

0.1285 (0.23%)

XLY

Consumer Discretionary Sector SPDR

$116.98

-0.4288 (-0.37%)

XLB

S&P Select Materials SPDR

$60.54

-0.1312 (-0.22%)

XLF

Financial Select Sector

$28.73

-0.1175 (-0.41%)

XLV

Health Care Select Sector SPDR

$94.26

0.1571 (0.17%)

XLK

Technology Select Sector SPDR

$74.68

-0.2056 (-0.27%)

XLI

Industrial Select Sector SPDR

$79.71

0.2338 (0.29%)

GLD

SPDR Gold Trust

$113.48

-0.77 (-0.67%)

SLV

iShares Silver Trust

$13.44

-0.01 (-0.07%)

USO

United States Oil Fund

$14.95

0.145 (0.98%)

UNG

United States Natural Gas Fund

$24.60

0.235 (0.96%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$86.24

0.05 (0.06%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$114.72

0.04 (0.03%)

TLT

iShares 20+ Year Treasury Bond Fund

$117.12

-0.02 (-0.02%)

IEF

iShares 7-10 Year Treasury Bond ETF

$101.00

0.03 (0.03%)

SHY

iShares 1-3 Year Treasury Bond

$83.05

0.02 (0.02%)

IWD

iShares Russell 1000 Value

$129.51

0.13 (0.10%)

IWF

iShares Russell 1000 Growth

$155.30

-0.55 (-0.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OHGI

One Horizon Group

$0.18

-0.0088 (-4.63%)

17:34
09/21/18
09/21
17:34
09/21/18
17:34
Syndicate
Breaking Syndicate news story on One Horizon Group »

One Horizon Group files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYTX

Cytori Therapeutics

$0.41

-0.033 (-7.38%)

17:31
09/21/18
09/21
17:31
09/21/18
17:31
Syndicate
Breaking Syndicate news story on Cytori Therapeutics »

Cytori Therapeutics files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NEM

Newmont Mining

$31.56

0.05 (0.16%)

17:22
09/21/18
09/21
17:22
09/21/18
17:22
Syndicate
Breaking Syndicate news story on Newmont Mining »

Newmont Mining files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 25

    Oct

CB

Chubb

$139.87

-0.05 (-0.04%)

17:22
09/21/18
09/21
17:22
09/21/18
17:22
Hot Stocks
Chubb CEO Greenberg sells $8.6M in common stock »

Chubb CEO Evan Greenberg…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VTVT

vTv Therapeutics

$0.80

0.0096 (1.21%)

17:21
09/21/18
09/21
17:21
09/21/18
17:21
Hot Stocks
vTv says FDA advised that azeliragon efficacy be shown in at least 2 trials »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.